New treatment for severe lung disease-related high blood pressure
Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH)
This study is testing a new treatment for people with pulmonary hypertension caused by lung disease, aiming to make it easier for them to breathe and go about their daily lives by using a special medication that targets a substance involved in the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Halo Biosciences, INC. NIH-funded |
| Lab location | 1 site (Palo Alto, UNITED STATES) |
| Project ID | NIH-11088776 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for Group 3 pulmonary hypertension caused by interstitial lung disease (PH-ILD), a condition that severely limits patients' ability to breathe and perform daily activities. The approach involves targeting hyaluronan, a substance that contributes to the disease's progression, using a small molecule inhibitor called 4-MU. By improving the drug's effectiveness and bioavailability, the research aims to provide a more effective therapy for patients suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Group 3 pulmonary hypertension due to interstitial lung disease.
Not a fit: Patients with pulmonary hypertension not related to interstitial lung disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves the quality of life and survival rates for patients with PH-ILD.
How similar studies have performed: Previous research has shown promising results in animal models using similar approaches to target hyaluronan in pulmonary hypertension.
Where this research is happening
Palo Alto, UNITED STATES
- Halo Biosciences, INC. — Palo Alto, United States (Active)
Researchers
- Principal investigator: Paladini, Rudy — Halo Biosciences, INC.
- Study coordinator: Paladini, Rudy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.